Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $5.1 million.

  • Lisata Therapeutics' Cash from Investing Activities rose 18168.12% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 16876.02%. This contributed to the annual value of $13.2 million for FY2024, which is 3099.39% up from last year.
  • Per Lisata Therapeutics' latest filing, its Cash from Investing Activities stood at $5.1 million for Q3 2025, which was up 18168.12% from $505000.0 recorded in Q2 2025.
  • Over the past 5 years, Lisata Therapeutics' Cash from Investing Activities peaked at $12.3 million during Q3 2023, and registered a low of -$6.3 million during Q3 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was $4.3 million (2023), whereas its average is $3.5 million.
  • Within the past 5 years, the most significant YoY rise in Lisata Therapeutics' Cash from Investing Activities was 171558.62% (2024), while the steepest drop was 15146.1% (2024).
  • Quarter analysis of 3 years shows Lisata Therapeutics' Cash from Investing Activities stood at -$5.7 million in 2023, then skyrocketed by 124.31% to $1.4 million in 2024, then soared by 270.77% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $505000.0 for Q2 2025, and $9.4 million during Q1 2025.